Abstract
Background: There is very little known about SARS-CoV-2 vaccine immune responses in New Zealand populations at greatest risk for serious COVID-19 disease.
Methods: This prospective cohort study assessed immunogenicity in BNT162b2 mRNA vaccine recipients in New Zealand without previous COVID-19, with enrichment for Māori, Pacific peoples, older adults ≥ 65 years of age, and those with co-morbidities. Serum samples were analysed at baseline and 28 days after second dose for presence of quantitative anti-S IgG by chemiluminescent microparticle immunoassay and for neutralizing capacity against Wuhan, Beta, Delta, and Omicron BA.1 strains using a surrogate viral neutralisation assay.
Results: 285 adults with median age of 52 years were included. 55% were female, 30% were Māori, 28% were Pacific peoples, and 26% were ≥ 65 years of age. Obesity, cardiac and pulmonary disease and diabetes were more common than in the general population. All participants received 2 doses of BNT162b2 vaccine. At 28 days after second vaccination, 99.6% seroconverted to the vaccine, and anti-S IgG and neutralising antibody levels were high across gender and ethnic groups. IgG and neutralising responses declined with age. Lower responses were associated with age ≥ 75 and diabetes, but not BMI. The ability to neutralise the Omicron BA.1 variant in vitro was severely diminished but maintained against other variants of concern.
Conclusions: Vaccine antibody responses to BNT162b2 were generally robust and consistent with international data in this COVID-19 naïve cohort with representation of key populations at risk for COVID-19 morbidity. Subsequent data on response to boosters, durability of responses and cellular immune responses should be assessed with attention to elderly adults and diabetics.
Keywords: COVID-19; Immunogenicity; Māori; Pacific Islander; Vaccine.
【저자키워드】 COVID-19, immunogenicity, vaccine., Māori, Pacific Islander, 【초록키워드】 IgG, Vaccine, BNT162b2 vaccine, immune response, immunogenicity, Ethnic groups, Older adults, Cellular immune response, obesity, Antibody Response, variant, Delta, Gender, risk, diabetes, in vitro, prospective cohort study, omicron, SARS-CoV-2 vaccine, Population, COVID-19 disease, BNT162b2, immunoassay, Cohort, Viral, neutralising antibody, immune responses, response, International, Wuhan, morbidity, female, Beta, age, neutralizing capacity, General population, BMI, disease, Quantitative, co-morbidities, BNT162b2 mRNA vaccine, anti-S IgG, pulmonary disease, dose, strain, Older, serum samples, diabetics, second vaccination, second dose, All participants, enrichment, other variants, median age, morbidities, naïve, serious COVID-19, neutralising responses, viral neutralisation, cellular immune responses, recipient, Lower, serum sample, Microparticle, representation, robust, analysed, seroconverted, the vaccine, New, diabete, other variant, declined, All participant, baseline, neutralise, neutralising response, of BNT162b2, 【제목키워드】 COVID-19 vaccine, New, of BNT162b2,